Susquehanna International Group
MLYS icon

Susquehanna International Group’s Mineralys Therapeutics MLYS Stock Holding History

Susquehanna International Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.8M Buy
692,600
+208,900
+43% +$6.13M ﹤0.01% 2317
2025
Q4 		$17.6M Buy
+483,700
New +$19.4M ﹤0.01% 2350
2025
Q2 		– Sell
-13,000
Closed -$206K – 13323
2025
Q1 		$206K Buy
+13,000
New +$150K ﹤0.01% 10870

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Susquehanna International Group's MLYS Position: Q1 2026 in Review

Susquehanna International Group reduced its Mineralys Therapeutics (MLYS) stake by 89% in Q1 2026, selling an estimated $3.74M and leaving 15,770 shares worth $427K. The position accounts for ﹤0.01% of the portfolio, ranked #10050.

Susquehanna International Group first reported a position in MLYS in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.2M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Susquehanna International Group held 15,770 shares of Mineralys Therapeutics worth $427K as of Q1 2026.
  • Susquehanna International Group sold 127,438 Mineralys Therapeutics shares in Q1 2026, an estimated $3.74M.
  • Mineralys Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10050 holding.
  • Susquehanna International Group first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Susquehanna International Group's Mineralys Therapeutics position peaked at $5.2M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.